Vor Biopharma (VOR) 10-Q 10 Aug 23 2023 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 10, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Registrant Name	VOR BIOPHARMA INC.
Entity Central Index Key	0001817229
Entity File Number	001-39979
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-1591163
Entity Address, Address Line One	100 Cambridgepark Drive
Entity Address, Address Line Two	Suite 101
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02140
City Area Code	617
Local Phone Number	655-6580
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		67,538,680
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	VOR
Security Exchange Name	NASDAQ

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 32,212	$ 57,706
Marketable securities	154,690	172,539
Prepaid expenses	3,952	4,368
Other current assets	539	2,337
Total current assets	191,393	236,950
Restricted cash equivalents	2,413	2,413
Property and equipment, net	11,458	12,634
Operating lease right-of-use assets	42,454	44,444
Other assets	3,268	2,925
Total assets	250,986	299,366
Current liabilities:
Accounts payable	1,648	1,772
Accrued liabilities	7,256	7,889
Operating lease liabilities	3,691	3,272
Other current liabilities	122	186
Total current liabilities	12,717	13,119
Long-term liabilities:
Operating lease liabilities—non-current	33,819	35,640
Total liabilities	46,536	48,759
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 0 shares issued and outstanding as of March 31, 2023 and December 31, 2022
Common stock, $0.0001 par value; 400,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 66,991,060 and 66,079,597 shares issued and 66,934,897 and 65,996,138 outstanding as of March 31, 2023 and December 31, 2022, respectively	7	7
Additional paid-in capital	485,508	473,587
Accumulated other comprehensive loss	(436)	(770)
Accumulated deficit	(280,629)	(222,217)
Total stockholders' equity	204,450	250,607
Total liabilities and stockholders' equity	$ 250,986	$ 299,366

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	67,464,265	66,079,597
Common stock, shares outstanding	67,433,560	65,996,138

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Research and development	$ 23,897	$ 15,333	$ 45,812	$ 30,613
General and administrative	8,277	6,459	16,784	13,979
Total operating expenses	32,174	21,792	62,596	44,592
Loss from operations	(32,174)	(21,792)	(62,596)	(44,592)
Other income:
Interest income	2,195	133	4,184	196
Total other income	2,195	133	4,184	196
Net loss	$ (29,979)	$ (21,659)	$ (58,412)	$ (44,396)
Net loss per share attributable to common stockholders, basic	$ (0.45)	$ (0.58)	$ (0.88)	$ (1.19)
Net loss per share attributable to common stockholders, diluted	$ (0.45)	$ (0.58)	$ (0.88)	$ (1.19)
Weighted-average number of common shares outstanding, basic	67,033,150	37,437,063	66,651,547	37,365,647
Weighted-average number of common shares outstanding, diluted	67,033,150	37,437,063	66,651,547	37,365,647
Other comprehensive income (loss):
Unrealized gain (loss) on available for sale investments	$ (262)	$ (254)	$ 334	$ (1,326)
Total other comprehensive income (loss)	(262)	(254)	334	(1,326)
Comprehensive loss	$ (30,241)	$ (21,913)	$ (58,078)	$ (45,722)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning Balance at Dec. 31, 2021	$ 216,263	$ 4	$ 346,382		$ (130,123)
Beginning Balance, Shares at Dec. 31, 2021		37,174,741
Issuance of common stock upon vesting and exercise of stock options	247		247
Issuance of common stock upon vesting and exercise of stock options, Shares		161,573
Stock-based compensation expense	1,746		1,746
Other comprehensive income (loss)	(1,072)			$ (1,072)
Net loss	(22,737)				(22,737)
Ending Balance at Mar. 31, 2022	194,447	$ 4	348,375	(1,072)	(152,860)
Ending Balance, Shares at Mar. 31, 2022		37,336,314
Beginning Balance at Dec. 31, 2021	216,263	$ 4	346,382		(130,123)
Beginning Balance, Shares at Dec. 31, 2021		37,174,741
Other comprehensive income (loss)	(1,326)
Net loss	(44,396)
Ending Balance at Jun. 30, 2022	174,974	$ 4	350,815	(1,326)	(174,519)
Ending Balance, Shares at Jun. 30, 2022		37,506,236
Beginning Balance at Mar. 31, 2022	194,447	$ 4	348,375	(1,072)	(152,860)
Beginning Balance, Shares at Mar. 31, 2022		37,336,314
Issuance of common stock upon vesting and exercise of stock options	146		146
Issuance of common stock upon vesting and exercise of stock options, Shares		74,358
Issuance of common stock from open market sales agreeement	553		553
Issuance of common stock from open market sales agreeement, Shares		95,564
Stock-based compensation expense	1,741		1,741
Other comprehensive income (loss)	(254)			(254)
Net loss	(21,659)				(21,659)
Ending Balance at Jun. 30, 2022	174,974	$ 4	350,815	(1,326)	(174,519)
Ending Balance, Shares at Jun. 30, 2022		37,506,236
Beginning Balance at Dec. 31, 2022	$ 250,607	$ 7	473,587	(770)	(222,217)
Beginning Balance, Shares at Dec. 31, 2022	65,996,138	65,996,138
Issuance of common stock upon vesting of RSUs and exercise of stock options, net of shares withheld for taxes	$ (340)		(340)
Issuance of common stock upon vesting of RSUs and exercise of stock options, net of shares withheld for taxes, Shares		205,485
Issuance of common stock from open market sales agreeement	3,717		3,717
Issuance of common stock from open market sales agreeement, Shares		733,274
Stock-based compensation expense	4,068		4,068
Other comprehensive income (loss)	596			596
Net loss	(28,433)				(28,433)
Ending Balance at Mar. 31, 2023	230,215	$ 7	481,032	(174)	(250,650)
Ending Balance, Shares at Mar. 31, 2023		66,934,897
Beginning Balance at Dec. 31, 2022	$ 250,607	$ 7	473,587	(770)	(222,217)
Beginning Balance, Shares at Dec. 31, 2022	65,996,138	65,996,138
Other comprehensive income (loss)	$ 334
Net loss	(58,412)
Ending Balance at Jun. 30, 2023	$ 204,450	$ 7	485,508	(436)	(280,629)
Ending Balance, Shares at Jun. 30, 2023	67,433,560	67,433,560
Beginning Balance at Mar. 31, 2023	$ 230,215	$ 7	481,032	(174)	(250,650)
Beginning Balance, Shares at Mar. 31, 2023		66,934,897
Issuance of common stock from open market sales agreeement	555		555
Issuance of common stock from open market sales agreeement, Shares		116,888
Issuance of common stock upon vesting of RSUs, vesting and exercise of stock options, and issuance of common stock from ESSP, net of shares withheld for taxes	(317)		(317)
Issuance of common stock upon vesting of RSUs, vesting and exercise of stock options, and issuance of common stock from ESSP, net of shares withheld for taxes, shares		381,775
Stock-based compensation expense	4,238		4,238
Other comprehensive income (loss)	(262)			(262)
Net loss	(29,979)				(29,979)
Ending Balance at Jun. 30, 2023	$ 204,450	$ 7	$ 485,508	$ (436)	$ (280,629)
Ending Balance, Shares at Jun. 30, 2023	67,433,560	67,433,560

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net loss	$ (58,412)	$ (44,396)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation expense	1,707	1,001
Amortization of operating lease right-of-use assets	2,317	1,311
Stock-based compensation	8,306	3,487
Interest (amortization) accretion on marketable securities	(2,447)	120
Changes in operating assets and liabilities:
Operating lease liabilities, net	(1,729)	(7,037)
Prepaid expenses and other current assets	2,214	(728)
Accounts payable and accrued liabilities	19	(1,473)
Other assets	(343)	(181)
Net cash used in operating activities	(48,368)	(47,896)
Cash flow from investing activities
Purchases of marketable securities	(58,370)	(5,044)
Proceeds from maturities of marketable securities	79,000	3,130
Purchases of property and equipment	(493)	(7,843)
Net cash provided by (used in) investing activities	20,137	(9,757)
Cash flow from financing activities
Payment of issuance costs related to underwritten public offering and concurrent private placement	(717)
Proceeds from the issuance of common stock from at-the-market sales agreement, net of issuance costs	4,201	504
Shares repurchased for tax withholdings upon vesting of restricted stock unit awards	(945)
Proceeds from stock option exercises and the issuance of shares under ESPP	198	300
Net cash provided by financing activities	2,737	804
Net decrease in cash, cash equivalents and restricted cash equivalents	(25,494)	(56,849)
Cash, cash equivalents and restricted cash equivalents, beginning of period	60,119	122,214
Cash, cash equivalents and restricted cash equivalents, end of period	34,625	65,365
Supplemental disclosure of non-cash activities
Right-of-use assets obtained in exchange for lease obligations	107	23,376
Purchases of property and equipment in accounts payable and accrued liabilities		$ 1,331
Financing costs associated with the sale of common stock included in accounts payable and accrued expenses	$ 24

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	$ 32,212	$ 57,706	$ 62,952
Restricted cash equivalents	2,413	2,413	2,413
Total cash, cash equivalents and restricted cash equivalents as shown on the statements of cash flows	$ 34,625	$ 60,119	$ 65,365	$ 122,214

Nature of the Business

Nature of the Business	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Nature of the Business	1. Nature of the Business Vor Biopharma Inc. (the “Company”) is a clinical-stage cell and genome engineering company that combines a novel patient engineering approach with targeted therapies to provide a single company solution for patients suffering from hematological malignancies. The Company’s proprietary platform leverages its expertise in hematopoietic stem cell (“HSC”) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company is headquartered in Cambridge, Massachusetts. The Company was incorporated on December 30, 2015 . Risks and Uncertainties The Company is subject to a number of risks common to development stage companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, dependence on key personnel, protection of proprietary technology, reliance on third party organizations, risks of obtaining regulatory approval for any product candidate that it may develop, development by competitors of technological innovations, compliance with government regulations, geopolitical tensions, adverse macroeconomic conditions and the need to obtain additional financing. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates. The Company believes that its existing cash, cash equivalents and marketable securities at June 30, 2023 will be sufficient to allow the Company to fund its current operations through at least a period of one year after the date the financial statements are issued.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Certain comparative amounts have been reclassified to conform to the current period presentation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies in developing the estimates and assumptions that are used in the preparation of the condensed consolidated financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: accrued expenses and research and development expenses. Unaudited Interim Financial Information The condensed consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. The accompanying condensed consolidated balance sheet as of December 31, 2022 has been derived from the Company’s audited consolidated financial statements for the year ended December 31, 2022. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report”). During the six months ended June 30, 2023, there have been no changes to the Company’s significant accounting policies as described in the 2022 Annual Report.

Marketable Securities

Marketable Securities	6 Months Ended
	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	3. Marketable Securities The amortized cost and estimated fair value of marketable securities, by contractual maturity are as follows: June 30, 2023 (in thousands) Amortized Cost Gross Unrealized Holding Gains Gross Unrealized Holding Losses Fair Value Maturing in one year or less U.S. Treasuries $ 155,126 $ 10 $ ( 446 ) $ 154,690 Total $ 155,126 $ 10 $ ( 446 ) $ 154,690 December 31, 2022 (in thousands) Amortized Cost Gross Unrealized Holding Gains Gross Unrealized Holding Losses Fair Value Maturing in one year or less Corporate bonds $ 5,001 $ — $ ( 56 ) $ 4,945 U.S. Treasuries 116,432 — ( 617 ) 115,815 Maturing after one year through five years U.S. Treasuries 51,876 — ( 97 ) 51,779 Total $ 173,309 $ — $ ( 770 ) $ 172,539 The unrealized losses of the Company’s marketable securities above were a result of market interest rate increases. The contractual terms of those investments do not permit the issuer to settle the securities at a price less than par value. The Company’s intent is to hold the investments until their maturity and any change in fair value that is not credit related is recognized as other comprehensive income (loss), net of applicable taxes. A credit-related impairment is recognized as an allowance to the balance sheet with a corresponding adjustment to earnings. The Company did no t recognize any credit losses related to marketable securities for the six months ended June 30, 2023 .

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis: June 30, 2023 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents Money market funds $ 31,543 $ — $ — $ 31,543 Marketable securities U.S. Treasuries — 154,690 — 154,690 Total marketable securities — 154,690 — 154,690 Restricted cash equivalents Money market funds 2,413 — — 2,413 Total $ 33,956 $ 154,690 $ — $ 188,646 December 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents Money market funds $ 46,981 $ — $ — $ 46,981 Marketable securities Corporate bonds — 4,945 — 4,945 U.S. Treasuries — 167,594 — 167,594 Total marketable securities — 172,539 — 172,539 Restricted cash equivalents Money market funds 2,413 — — 2,413 Total $ 49,394 $ 172,539 $ — $ 221,933 The fair value of the Company’s cash equivalents and restricted cash equivalents is based on quoted market prices in active markets with no valuation adjustment. The fair value of investments was determined based on observable market inputs. There were no transfers between levels during the six months ended June 30, 2023. Cash equivalents, restricted cash, prepaid expenses, accounts payable and accrued expenses are stated at their respective historical carrying values, which approximate fair value due to their short-term nature.

Property and Equipment, Net

Property and Equipment, Net	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	5. Property and Equipment, Net Property and equipment, net consisted of the following: June 30, December 31, (in thousands) 2023 2022 Laboratory equipment $ 9,937 $ 9,499 Manufacturing equipment 6,817 5,706 Computer equipment 432 432 Furniture, fixtures and other 568 568 Construction in progress 11 1,039 Total 17,765 17,244 Less: Accumulated depreciation ( 6,307 ) ( 4,610 ) Property and equipment, net $ 11,458 $ 12,634 Depreciation expense for the three and six months ended June 30, 2023 was $ 0.9 million and $ 1.7 million, respectively, and for the three and six months ended June 30, 2022 was $ 0.6 million and $ 1.0 million, respectively.

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
Accrued Liabilities	6. Accrued Liabilities Accrued liabilities consisted of the following: June 30, December 31, (in thousands) 2023 2022 Employee-related expenses $ 3,123 $ 4,408 Professional fees 1,318 1,701 Clinical expenses 1,241 532 Research and development expenses 473 569 Manufacturing expenses 955 328 Other 146 351 Total accrued liabilities $ 7,256 $ 7,889

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	7. Stock-Based Compensation Stock Incentive Plan As of June 30, 2023, the Company had 796,957 shares of its common stock available for future issuance under its stock incentive plan. Stock Options The Company’s stock options generally vest over 48 months with 25 % vesting after one year followed by ratable monthly vesting over the remaining three years and have a contractual term of 10 years. The weighted-average assumptions used principally in determining the fair value of options granted were as follows: Six Months Ended June 30, 2023 2022 Fair value of common stock $ 3.76 $ 8.30 Expected term (in years) 6.0 6.0 Expected volatility 81.9 % 78.4 % Risk-free interest rate 3.7 % 1.8 % Dividend yield — — During the six months ended June 30, 2023 and 2022, the Company granted stock options to purchase 2,108,219 shares and 1,948,264 shares of its common stock, respectively, with a weighted-average grant-date fair value of $ 3.76 and $ 5.65 per share, respectively. As of June 30, 2023, total unrecognized compensation expense related to stock options was $ 19.2 million , which is expected to be recognized over a weighted-average period of 2.4 years. As of June 30, 2023, options for 30,704 shares of Company common stock with a weighted-average exercise price of $ 1.36 were exercised and unvested. The underlying proceeds from the unvested exercises of $ 0.1 million is recorded in other current liabilities on the condensed consolidated balance sheet. Restricted Stock Units During the six months ended June 30, 2023 and 2022, the Company granted 645,360 restricted stock units and 1,040,500 restricted stock units, respectively, with a weighted-average grant date fair value of $ 5.55 and $ 6.00 per share, respectively. As of June 30, 2023, total unrecognized compensation expense related to restricted stock units was $ 6.2 million , which is expected to be recognized over a weighted-average period of 1.8 years. Employee Stock Purchase Plan As of June 30, 2023, the Company had 666,535 shares of its common stock available for issuance under its Employee Stock Purchase Plan (“ESPP”). During the six months ended June 30, 2023, the Company issued 44,977 shares with a weighted-average purchase price of $ 3.76 under the ESPP, which resulted in an immaterial amount of compensation expense. The Company did no t issue any shares under the ESPP during the six months ended June 30, 2022. Stock-Based Compensation Stock-based compensation expense was allocated as follows: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2023 2022 2023 2022 Research and development $ 2,463 $ 909 $ 4,817 $ 1,705 General and administrative 1,775 832 3,489 1,782 Total stock-based compensation expense $ 4,238 $ 1,741 $ 8,306 $ 3,487

Leases

Leases	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Leases	8. Leases Cambridgepark Lease Amendments On June 15, 2021, the Company entered into the first lease amendment (“First Lease Amendment”) and second lease amendment (“Second Lease Amendment” and, together with the First Lease Amendment, the “Lease Amendments”) with PPF Off 100 Cambridge Park Drive, LLC (the “Landlord”). The Lease Amendments amended the Company’s lease agreement for its corporate office and laboratory facilities with the Landlord in Cambridge, Massachusetts to add additional leased space in the same building (the “Amended Cambridgepark Lease”). The First Lease Amendment and Second Lease Amendment commenc ed for accounting purposes on January 28, 2022 and April 29, 2022 , respectively. The terms of the Lease Amendments are through September 2030 for approximately $ 8.4 million and $ 22.3 million in fixed payments for the First Lease Amendment and Second Lease Amendment, respectively. There are no options to extend the Lease Amendments. Payments due associated with the Lease Amendments include fixed and variable payments. Variable payments relate to the Company’s share of the Landlord’s operating costs associated with the underlying assets and are recognized when the event on which those payments are assessed. The Amended Cambridgepark Lease does not contain a residual value guarantee. The Lease Amendments term end dates are coterminous with the existing lease agreement. In conjunction with the Lease Amendments, the Company was required to increase its irrevocable standby letter of credit to $ 2.4 million for the benefit of the Landlord, which has been secured by money market investments and is presented as restricted cash equivalents. For further information regarding the Company’s Cambridgepark lease, please see Note 9 to the consolidated financial statements included in the 2022 Annual Report. The elements of lease expense were as follows: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2023 2022 2023 2022 Operating lease cost $ 1,948 $ 1,592 $ 3,901 $ 2,512 Variable lease cost 661 301 1,258 642 Total lease cost $ 2,609 $ 1,893 $ 5,159 $ 3,154 Amounts reported in the condensed consolidated balance sheets and the weighted-average lease term and discount rate information were as follows: (in thousands except weighted-average amounts) June 30, 2023 December 31, 2022 Assets Operating lease right-of-use assets $ 42,454 $ 44,444 Liabilities Operating lease liabilities, current $ 3,691 $ 3,272 Operating lease liabilities, non-current 33,819 35,640 Total lease liabilities $ 37,510 $ 38,912 Weighted-Average Lease Term and Discount Rate Weighted-average remaining lease term (years) 7.2 7.7 Weighted-average discount rate 8.2 % 8.2 % The following table represents other lease activity: Six Months Ended June 30, (in thousands) 2023 2022 Other Information Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 3,312 $ 8,522 Right-of-use assets obtained in exchange for lease obligations $ 107 $ 23,376

Significant Agreements

Significant Agreements	6 Months Ended
	Jun. 30, 2023
Significant Agreements [Abstract]
Significant Agreements	9. Significant Agreements Since December 31, 2022, there have been no material changes to the key terms of the Company’s license agreements. For further information regarding the Company’s existing license agreements, please see Note 10 to the consolidated financial statements included in the 2022 Annual Report.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	10. Net Loss Per Share The following table sets forth the computation of the Company’s basic and diluted net loss per share for the three and six months ended June 30, 2023 and 2022: Three Months Ended June 30, Six Months Ended June 30, (in thousands, except share and per share amounts) 2023 2022 2023 2022 Numerator: Net loss attributable to common stockholders $ ( 29,979 ) $ ( 21,659 ) $ ( 58,412 ) $ ( 44,396 ) Denominator: Weighted-average number of common shares outstanding, basic and diluted 67,033,150 37,437,063 66,651,547 37,365,647 Net loss per share attributable to common stockholders, basic and diluted $ ( 0.45 ) $ ( 0.58 ) $ ( 0.88 ) $ ( 1.19 ) The Company’s potentially dilutive securities were stock options, unvested restricted stock and restricted stock units. Based on the amounts outstanding as of June 30, 2023 and 2022, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: As of June 30, 2023 2022 Options to purchase common stock 8,368,063 5,893,016 Unvested restricted stock 30,704 138,052 Restricted stock units 1,324,361 1,040,500

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Certain comparative amounts have been reclassified to conform to the current period presentation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies in developing the estimates and assumptions that are used in the preparation of the condensed consolidated financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: accrued expenses and research and development expenses.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The condensed consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. The accompanying condensed consolidated balance sheet as of December 31, 2022 has been derived from the Company’s audited consolidated financial statements for the year ended December 31, 2022. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report”). During the six months ended June 30, 2023, there have been no changes to the Company’s significant accounting policies as described in the 2022 Annual Report.

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Summary of Amortized Cost and Estimated Fair Value of Marketable Securities by Contractual Maturity	The amortized cost and estimated fair value of marketable securities, by contractual maturity are as follows: June 30, 2023 (in thousands) Amortized Cost Gross Unrealized Holding Gains Gross Unrealized Holding Losses Fair Value Maturing in one year or less U.S. Treasuries $ 155,126 $ 10 $ ( 446 ) $ 154,690 Total $ 155,126 $ 10 $ ( 446 ) $ 154,690 December 31, 2022 (in thousands) Amortized Cost Gross Unrealized Holding Gains Gross Unrealized Holding Losses Fair Value Maturing in one year or less Corporate bonds $ 5,001 $ — $ ( 56 ) $ 4,945 U.S. Treasuries 116,432 — ( 617 ) 115,815 Maturing after one year through five years U.S. Treasuries 51,876 — ( 97 ) 51,779 Total $ 173,309 $ — $ ( 770 ) $ 172,539

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis: June 30, 2023 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents Money market funds $ 31,543 $ — $ — $ 31,543 Marketable securities U.S. Treasuries — 154,690 — 154,690 Total marketable securities — 154,690 — 154,690 Restricted cash equivalents Money market funds 2,413 — — 2,413 Total $ 33,956 $ 154,690 $ — $ 188,646 December 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Cash equivalents Money market funds $ 46,981 $ — $ — $ 46,981 Marketable securities Corporate bonds — 4,945 — 4,945 U.S. Treasuries — 167,594 — 167,594 Total marketable securities — 172,539 — 172,539 Restricted cash equivalents Money market funds 2,413 — — 2,413 Total $ 49,394 $ 172,539 $ — $ 221,933

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following: June 30, December 31, (in thousands) 2023 2022 Laboratory equipment $ 9,937 $ 9,499 Manufacturing equipment 6,817 5,706 Computer equipment 432 432 Furniture, fixtures and other 568 568 Construction in progress 11 1,039 Total 17,765 17,244 Less: Accumulated depreciation ( 6,307 ) ( 4,610 ) Property and equipment, net $ 11,458 $ 12,634

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following: June 30, December 31, (in thousands) 2023 2022 Employee-related expenses $ 3,123 $ 4,408 Professional fees 1,318 1,701 Clinical expenses 1,241 532 Research and development expenses 473 569 Manufacturing expenses 955 328 Other 146 351 Total accrued liabilities $ 7,256 $ 7,889

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Weighted-Average Assumptions Used Principally in Determining Fair Value of Options Granted	The weighted-average assumptions used principally in determining the fair value of options granted were as follows: Six Months Ended June 30, 2023 2022 Fair value of common stock $ 3.76 $ 8.30 Expected term (in years) 6.0 6.0 Expected volatility 81.9 % 78.4 % Risk-free interest rate 3.7 % 1.8 % Dividend yield — —
Summary of Stock-Based Compensation Expense	Stock-based compensation expense was allocated as follows: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2023 2022 2023 2022 Research and development $ 2,463 $ 909 $ 4,817 $ 1,705 General and administrative 1,775 832 3,489 1,782 Total stock-based compensation expense $ 4,238 $ 1,741 $ 8,306 $ 3,487

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Summary of Lease Expense	The elements of lease expense were as follows: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2023 2022 2023 2022 Operating lease cost $ 1,948 $ 1,592 $ 3,901 $ 2,512 Variable lease cost 661 301 1,258 642 Total lease cost $ 2,609 $ 1,893 $ 5,159 $ 3,154
Summary of Amounts Reported in Condensed Consolidated Balance Sheets and Weighted-average Lease Term and Discount rate Information	Amounts reported in the condensed consolidated balance sheets and the weighted-average lease term and discount rate information were as follows: (in thousands except weighted-average amounts) June 30, 2023 December 31, 2022 Assets Operating lease right-of-use assets $ 42,454 $ 44,444 Liabilities Operating lease liabilities, current $ 3,691 $ 3,272 Operating lease liabilities, non-current 33,819 35,640 Total lease liabilities $ 37,510 $ 38,912 Weighted-Average Lease Term and Discount Rate Weighted-average remaining lease term (years) 7.2 7.7 Weighted-average discount rate 8.2 % 8.2 %
Summary of Other Lease Activity	The following table represents other lease activity: Six Months Ended June 30, (in thousands) 2023 2022 Other Information Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 3,312 $ 8,522 Right-of-use assets obtained in exchange for lease obligations $ 107 $ 23,376

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of the Company’s basic and diluted net loss per share for the three and six months ended June 30, 2023 and 2022: Three Months Ended June 30, Six Months Ended June 30, (in thousands, except share and per share amounts) 2023 2022 2023 2022 Numerator: Net loss attributable to common stockholders $ ( 29,979 ) $ ( 21,659 ) $ ( 58,412 ) $ ( 44,396 ) Denominator: Weighted-average number of common shares outstanding, basic and diluted 67,033,150 37,437,063 66,651,547 37,365,647 Net loss per share attributable to common stockholders, basic and diluted $ ( 0.45 ) $ ( 0.58 ) $ ( 0.88 ) $ ( 1.19 )
Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share	The Company’s potentially dilutive securities were stock options, unvested restricted stock and restricted stock units. Based on the amounts outstanding as of June 30, 2023 and 2022, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: As of June 30, 2023 2022 Options to purchase common stock 8,368,063 5,893,016 Unvested restricted stock 30,704 138,052 Restricted stock units 1,324,361 1,040,500

Nature of the Business - Additi

Nature of the Business - Additional Information (Details)	6 Months Ended
	Jun. 30, 2023
Nature Of Business [Line Items]
Incorporation date	Dec. 30, 2015

Marketable Securities - Summary

Marketable Securities - Summary of Amortized Cost and Estimated Fair Value of Marketable Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 155,126	$ 173,309
Gross Unrealized Holding Gains	10
Gross Unrealized Holding losses	(446)	(770)
Fair Value	154,690	172,539
Maturing in One Year or Less | Corporate Bonds
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		5,001
Gross Unrealized Holding losses		(56)
Fair Value		4,945
Maturing in One Year or Less | U.S. Treasuries
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	155,126	116,432
Gross Unrealized Holding Gains	10
Gross Unrealized Holding losses	(446)	(617)
Fair Value	$ 154,690	115,815
Maturing after One Year through Five Years | U.S. Treasuries
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		51,876
Gross Unrealized Holding losses		(97)
Fair Value		$ 51,779

Marketable Securities - Additio

Marketable Securities - Additional Information (Details)	6 Months Ended
	Jun. 30, 2023 USD ($)
Investments, Debt and Equity Securities [Abstract]
Credit losses related to marketable securities	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	$ 188,646	$ 221,933
Marketable Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	154,690	172,539
Marketable Securities | Corporate Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total		4,945
Marketable Securities | U.S. Treasuries
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	154,690	167,594
Cash Equivalents | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	31,543	46,981
Restricted Cash Equivalents | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	2,413	2,413
Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	33,956	49,394
Level 1 | Cash Equivalents | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	31,543	46,981
Level 1 | Restricted Cash Equivalents | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	2,413	2,413
Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	154,690	172,539
Level 2 | Marketable Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	154,690	172,539
Level 2 | Marketable Securities | Corporate Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total		4,945
Level 2 | Marketable Securities | U.S. Treasuries
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	$ 154,690	$ 167,594

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details)	6 Months Ended
	Jun. 30, 2023 USD ($)
Fair Value Disclosures [Abstract]
Fair value assets, level 1 to level 2 transfers amount	$ 0
Fair value assets, level 2 to level 1 transfers amount	0
Fair value assets, transfers into level 3	0
Fair value assets, transfers out of level 3	$ 0

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Total	$ 17,765	$ 17,244
Less: Accumulated depreciation	(6,307)	(4,610)
Property and equipment, net	11,458	12,634
Laboratory Equipment
Property Plant And Equipment [Line Items]
Total	9,937	9,499
Manufacturing Equipment
Property Plant And Equipment [Line Items]
Total	6,817	5,706
Computer Equipment
Property Plant And Equipment [Line Items]
Total	432	432
Furniture, Fixtures and Other
Property Plant And Equipment [Line Items]
Total	568	568
Construction in Progress
Property Plant And Equipment [Line Items]
Total	$ 11	$ 1,039

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 900	$ 600	$ 1,707	$ 1,001

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Employee-related expenses	$ 3,123	$ 4,408
Professional fees	1,318	1,701
Clinical expenses	1,241	532
Research and development expenses	473	569
Manufacturing expenses	955	328
Other	146	351
Total accrued liabilities	$ 7,256	$ 7,889

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	2,108,219	1,948,264
Weighted-average grant-date fair value of options granted	$ 3.76	$ 5.65
Unrecognized compensation expense related to stock options	$ 19.2
Unrecognized share based compensation expense, recognition period	2 years 4 months 24 days
Number unvested options	30,704
Weighted average exercise price of options exercised and unvested	$ 1.36
Proceeds from unvested options exercises	$ 0.1
Employee Stock Purchase Plan 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares issued	44,977	0
Weighted average purchase price	$ 3.76
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting rights description	vest over 48 months with 25% vesting after one year followed by ratable monthly vesting over the remaining three years
Vesting period	48 months
Contractual term	10 years
Weighted-average grant-date fair value of options granted	$ 3.76	$ 8.3
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized share based compensation expense, recognition period	1 year 9 months 18 days
Restricted stock units granted	645,360	1,040,500
Weighted average grant date fair value of restricted stock, granted	$ 5.55	$ 6
Unrecognized compensation expense related to related to restricted stock units	$ 6.2
Common Stock | Employee Stock Purchase Plan 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for future issuance	666,535
Tranche One | Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	1 year
Vesting percentage	25%
Tranche Two | Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	3 years
2021 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for future issuance	796,957

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Weighted-Average Assumptions Used Principally in Determining Fair Value of Options Granted (Details) - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock	$ 3.76	$ 5.65
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock	$ 3.76	$ 8.3
Expected term (in years)	6 years	6 years
Expected volatility	81.90%	78.40%
Risk-free interest rate	3.70%	1.80%
Dividend yield	0%	0%

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 4,238	$ 1,741	$ 8,306	$ 3,487
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	2,463	909	4,817	1,705
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,775	$ 832	$ 3,489	$ 1,782

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Millions			6 Months Ended
	Apr. 29, 2022	Jan. 28, 2022	Jun. 30, 2023
Standby Letters of Credit
Lessee Lease Description [Line Items]
Increase in irrevocable line of credit facility			$ 2.4
First Lease Amendment
Lessee Lease Description [Line Items]
Operating lease commencement date		Jan. 28, 2022
Aggregate total fixed rent payments		$ 8.4
Second Lease Amendment
Lessee Lease Description [Line Items]
Operating lease commencement date	Apr. 29, 2022
Aggregate total fixed rent payments	$ 22.3
Cambridgepark Lease
Lessee Lease Description [Line Items]
Lessee, Operating Lease, Existence of Option to Extend [true false]			false

Leases - Summary of Lease Expen

Leases - Summary of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Leases [Abstract]
Operating lease cost	$ 1,948	$ 1,592	$ 3,901	$ 2,512
Variable lease cost	661	301	1,258	642
Total lease cost	$ 2,609	$ 1,893	$ 5,159	$ 3,154

Leases - Summary of Amounts Rep

Leases - Summary of Amounts Reported in Condensed Consolidated Balance Sheets and Weighted-average Lease Term and Discount rate Information (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Assets
Operating lease right-of-use assets	$ 42,454	$ 44,444
Liabilities
Operating lease liabilities, current	3,691	3,272
Operating lease liabilities, non-current	33,819	35,640
Total lease liabilities	$ 37,510	$ 38,912
Weighted Average Lease Term and Discount Rate
Weighted-average remaining lease term (years)	7 years 2 months 12 days	7 years 8 months 12 days
Weighted-average discount rate	8.20%	8.20%

Leases - Summary of Other Lease

Leases - Summary of Other Lease Activity (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$ 3,312	$ 8,522
Right-of-use assets obtained in exchange for lease obligations	$ 107	$ 23,376

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Numerator:
Net loss attributable to common stockholders	$ (29,979)	$ (21,659)	$ (58,412)	$ (44,396)
Denominator, basic
Weighted-average number of common shares outstanding, basic	67,033,150	37,437,063	66,651,547	37,365,647
Net loss per share attributable to common stockholders, basic	$ (0.45)	$ (0.58)	$ (0.88)	$ (1.19)
Denominator, diluted
Weighted-average number of common shares outstanding, diluted	67,033,150	37,437,063	66,651,547	37,365,647
Net loss per share attributable to common stockholders, diluted	$ (0.45)	$ (0.58)	$ (0.88)	$ (1.19)

Net Loss Per Share - Potential

Net Loss Per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per share	8,368,063	5,893,016
Unvested Restricted Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per share	30,704	138,052
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per share	1,324,361	1,040,500